• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Braftovi (encorafenib) + Mektovi (binimetinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Braftovi (encorafenib) + Mektovi (binimetinib)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor. Mektovi (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). 

    Braftovi + Mektovi is specifically indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

    Braftovi is supplied as a capsule for oral administration. Mektovi is supplied as a tablet for oral administration. The recommended dosage of Braftovi is 450 mg orally taken once daily in combination with binimetinib until disease progression or unacceptable toxicity. Braftovi may be taken with or without food. Do not take a missed dose of Braftovi within 12 hours of the next dose of Braftovi. Do not take an additional dose if vomiting occurs after Braftovi administration but continue with the next scheduled dose. The recommended dosage of Mektovi is 45 mg orally taken twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Mektovi may be taken with or without food. Do not take a missed dose of Mektovi within 6 hours of the next dose of Mektovi. Do not take an additional dose if vomiting occurs after Mektovi administration but continue with the next scheduled dose. 

    Clinical Results

    FDA Approval

    The FDA approval of Braftovi and Mektovi was based on a randomized, active-controlled, open-label, multicenter trial (COLUMBUS). Patients were required to have BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Patients were permitted to have received immunotherapy in the adjuvant setting and one prior line of immunotherapy for unresectable locally advanced or metastatic disease. Prior use of BRAF inhibitors or MEK inhibitors was prohibited. Patients were randomized (1:1:1) to receive Braftovi 450 mg once daily in combination with binimetinib 45 mg twice daily, Braftovi 300 mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity. Only the results of the approved dosing (Braftovi 450 mg in combination with binimetinib 45 mg) are described below. The major efficacy outcome measure was progression-free survival (PFS) of Braftovi in combination with binimetinib compared with vemurafenib as assessed by a blinded independent central review. Braftovi in combination with binimetinib demonstrated a statistically significant improvement in PFS compared to vemurafenib (14.9 vs. 7.3 months). In addition, patients in the combination therapy arm demonstrated superior overall response rate (63% vs. 40%), a longer duration of response (51 weeks vs. 31 weeks) and received a higher median dose intensity (100% vs. 99.6%) compared with the vemurafenib arm.

    Side Effects

    Adverse effects associated with the use of Braftovi + Mektovi may include, but are not limited to, the following:

    fatigue

    nausea

    vomiting

    abdominal pain

    arthralgia

    Mechanism of Action

    Braftovi (encorafenib) is an oral small molecule BRAF kinase inhibitor. Mektovi (binimetinib) is an oral small molecule MEK inhibitor which target key enzymes in the MAPK signaling pathway (RAS-RAF-MEK-ERK). 

    Additional Information

    For additional information regarding Braftovi and Mektovi or unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, please visit https://www.braftovimektovi.com/

    Approval Date: 2018-06-01
    Company Name: Array BioPharma
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing